

Listing and evaluation of the results

1: Dr. med.Max Mustermann
Laboratory Mustermann

Survey of 21 October 2020

Adviser:

460

Cerebrospinal Fluid Analysis 01 - Protein Analysis

| Analyte | Sample | Unit | Your value | Target value | TV-Type | Lower limit | Upper limit | Deviation | Z-Score | Meets criteria | |
|---------------|--------|------|------------|--------------|---------|-------------|-------------|-----------|---------|----------------|--|
| Protein - CSF | 60 | mg/l | 1820 | 1748 | ET | 1346 | 2150 | 4.1% | 1,44 | + | |
| | 61 | | 330 | 315 | ET | 243 | 387 | 4.8% | 0,867 | + | |
| Albumin - CSF | 60 | mg/l | 1360 | 1252 | ET | 964 | 1540 | 8.6% | 2,37 | + | |
| | 61 | | 233 | 226 | ET | 174 | 278 | 3.1% | 0,716 | + | |
| IgG - CSF | 60 | mg/l | 235 | 205 | ET | 164 | 246 | 14.6% | 2,17 | + | |
| | 61 | | 38.7 | 36.4 | ET | 29.1 | 43.7 | 6.3% | 2,19 | + | |
| IgA - CSF | 60 | mg/l | 33.4 | 35.5 | ET | 25.9 | 45.1 | -5.9% | -1,71 | + | |
| | 61 | | 5.03 | 4.34 | tSV | 3.17 | 5.51 | 15.9% | 2,16 | + | |
| IgM - CSF | 60 | mg/l | 8.88 | 8.86 | tSV | 5.94 | 11.8 | 0.2% | 0,018 | + | |
| | 61 | | 2.17 | 2.03 | tSV | 1.36 | 2.70 | 6.9% | 0,704 | + | |
| Albumin | 60 | g/l | 34.4 | 34.0 | tSV | 27.2 | 40.8 | 1.2% | 0,28 | + | |
| | 61 | | 44.7 | 44.4 | tSV | 35.5 | 53.3 | 0.7% | 0,207 | + | |
| IgG | 60 | g/l | 10.5 | 10.5 | tSV | 8.61 | 12.4 | 0.0% | 0 | + | |
| | 61 | | 11.3 | 11.2 | tSV | 9.18 | 13.2 | 0.9% | 0,366 | + | |
| IgA | 60 | g/l | 1.48 | 1.44 | ET | 1.15 | 1.73 | 2.8% | 0,252 | + | |
| | 61 | | 1.92 | 1.90 | ET | 1.52 | 2.28 | 1.1% | 0,104 | + | |
| IgM | 60 | g/l | 0.730 | 0.740 | tSV | 0.548 | 0.932 | -1.4% | -0,25 | + | |
| | 61 | | 0.880 | 0.948 | tSV | 0.702 | 1.19 | -7.2% | -1,21 | + | |

| Analyte | Sample | Your unit | Stated value | Conversion factor | Method | Manufacturer | Device |
|---------------|--------|-----------|--------------|-------------------|--------|--------------|--------|
| Protein - CSF | 60 | | 1820 | 1.00 | 116 | RO | RO71 |
| | 61 | | 330 | 1.00 | | | |
| Albumin - CSF | 60 | | 1360 | 1.00 | 87 | BE | BE51 |
| | 61 | | 233 | 1.00 | | | |
| IgG - CSF | 60 | | 235 | 1.00 | 87 | BE | BE51 |
| | 61 | | 38.7 | 1.00 | | | |
| IgA - CSF | 60 | | 33.4 | 1.00 | 87 | BE | BE51 |
| | 61 | | 5.03 | 1.00 | | | |
| IgM - CSF | 60 | | 8.88 | 1.00 | 87 | BE | BE51 |
| | 61 | | 2.17 | 1.00 | | | |
| Albumin | 60 | | 34.4 | 1.00 | 87 | BE | BE51 |
| | 61 | | 44.7 | 1.00 | | | |
| IgG | 60 | | 10.5 | 1.00 | 87 | BE | BE51 |
| | 61 | | 11.3 | 1.00 | | | |
| IgA | 60 | | 1.48 | 1.00 | 87 | BE | BE51 |
| | 61 | | 1.92 | 1.00 | | | |
| IgM | 60 | | 0.730 | 1.00 | 87 | BE | BE51 |
| | 61 | | 0.880 | 1.00 | | | |



Listing and evaluation of the results

1: Dr. med.Max Mustermann
Laboratory Mustermann

Survey of 21 October 2020


| Analyte | Sample | Method | Manufacturer | Device | Your specification(s) | Correct specification(s) | TV-Type | Meets criteria |
|------------------------------|--------|--------|--------------|--------|---|--|---------|----------------|
| normal quotient of | 60 | | | | IgG, IgM | IgG, IgA, IgM | M | + |
| | 61 | | | | Albumin, IgG | Albumin | M | + |
| intrathecal synthesis of | 60 | | | | IgA | IgA, no evidence of intrathecal immunoglobulin synthesis | M | + |
| | 61 | | | | IgM | IgA, IgM, no evidence of intrathecal immunoglobulin synthesis | M | + |
| Interpretation of the report | 60 | | | | Blood/CSF-barrier dysfunction, inflammatory CNS process | Blood/CSF-barrier dysfunction | M | + |
| | 61 | | | | inflammatory CNS process | normal CSF, inflammatory CNS process, implausible combination of the quotients | M | + |





** BRAVO **

Listing and evaluation of the results

1: Dr. med.Max Mustermann
 Laboratory Mustermann
 Survey of 21 October 2020

Sample 60




| Analyte | Sample | Unit | Your value | Target value | TV-Type | Lower limit | Upper limit | Deviation | Z-Score | Meets criteria | |
|------------------|--------|------|------------|--------------|---------|-------------|-------------|-----------|---------|----------------|---|
| Albumin quotient | 60 | E-3 | 39.5 | 37.1 | tSV | 26.0 | 48.2 | 6.5% | 1,78 | + |  |
| IgG Quotient | 60 | E-3 | 22.4 | 19.5 | tSV | 13.7 | 25.4 | 14.9% | 2,69 | + |  |
| IgA Quotient | 60 | E-3 | 22.6 | 24.2 | ET | 16.9 | 31.5 | -6.6% | -0,696 | + |  |
| IgM Quotient | 60 | E-3 | 12.2 | 12.2 | tSV | 8.54 | 15.9 | 0.0% | 0 | + |  |

Listing and evaluation of the results

1: Dr. med.Max Mustermann
 Laboratory Mustermann
 Survey of 21 October 2020

Sample 61



| Analyte | Sample | Unit | Your value | Target value | TV-Type | Lower limit | Upper limit | Deviation | Z-Score | Meets criteria | |
|------------------|--------|------|------------|--------------|---------|-------------|-------------|-----------|---------|----------------|--|
| Albumin quotient | 61 | E-3 | 5.20 | 5.12 | tSV | 3.58 | 6.66 | 1.6% | 0,28 | + | |
| IgG Quotient | 61 | E-3 | 3.40 | 3.24 | tSV | 2.27 | 4.21 | 4.9% | 0,976 | + | |
| IgA Quotient | 61 | E-3 | 2.60 | 2.46 | ET | 1.72 | 3.20 | 5.7% | 0,403 | + | |
| IgM Quotient | 61 | E-3 | 2.50 | 2.16 | tSV | 1.51 | 2.81 | 15.7% | 2,74 | + | |

Individual summary of results

1: Dr. med. Max Mustermann
Laboratory Mustermann



Survey of 21 October 2020

460

Cerebrospinal Fluid Analysis 01 - Protein Analysis



| Protein - CSF (mg/l, N = 245) | | | | | | | | | | |
|-------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| ABBOTT | 60 | 1748 | 1346 - 2150 | 1864 | 2.06 | 20 | 90.0 | 90.0 | | |
| | 61 | 315 | 243 - 387 | 311 | 5.34 | 20 | 90.0 | | | |
| BECKMAN COULTER | 60 | 1748 | 1346 - 2150 | 1826 | 3.43 | 27 | 88.9 | 85.2 | | |
| | 61 | 315 | 243 - 387 | 323 | 6.84 | 27 | 85.2 | | | |
| SIEMENS (Bayer Health) | 60 | 1748 | 1346 - 2150 | 1246 | 61.4 | 8 | 75.0 | 75.0 | | |
| | 61 | 315 | 243 - 387 | 244 | 61.5 | 8 | 75.0 | | | |
| SIEMENS (Dade Behring) | 60 | 1748 | 1346 - 2150 | 1739 | 2.50 | 26 | 100 | 92.3 | | |
| | 61 | 315 | 243 - 387 | 345 | 4.78 | 26 | 92.3 | | | |
| ROCHE DIAGNOSTICS | 60 | 1748 | 1346 - 2150 | 1734 | 2.88 | 150 | 90.0 | 86.0 | | |
| | 61 | 315 | 243 - 387 | 310 | 5.58 | 150 | 89.3 | | | |
| other providers | 60 | 1748 | 1346 - 2150 | 1753 | 18.3 | 14 | 85.7 | 71.4 | | |
| | 61 | 315 | 243 - 387 | 325 | 17.4 | 14 | 78.6 | | | |

Rate of success: 85,7%



| Albumin - CSF (mg/l, N = 174) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 1252 | 964 - 1540 | 1326 | 3.44 | 17 | 100 | 100 | | |
| | 61 | 226 | 174 - 278 | 231 | 4.23 | 17 | 100 | | | |
| BINDING SITE, THE | 60 | 1252 | 964 - 1540 | 1269 | 3.25 | 13 | 100 | 92.3 | | |
| | 61 | 226 | 174 - 278 | 235 | 2.91 | 13 | 92.3 | | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 1252 | 964 - 1540 | 1287 | 5.69 | 89 | 95.5 | 94.4 | | |
| | 61 | 226 | 174 - 278 | 232 | 5.34 | 89 | 95.5 | | | |
| ROCHE DIAGNOSTICS | 60 | 1252 | 964 - 1540 | 1173 | 5.00 | 50 | 92.0 | 86.0 | | |
| | 61 | 226 | 174 - 278 | 210 | 5.38 | 50 | 86.0 | | | |
| other providers (1) | 60 | 1252 | 964 - 1540 | 805 | 81.9 | 5 | | | | |
| | 61 | 226 | 174 - 278 | 177 | 62.7 | 5 | | | | |



Rate of success: 91,4%



(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.



| IgG - CSF (mg/l, N = 157) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 205 | 164 - 246 | 210 | 6.57 | 16 | 93.8 | 93.8 | | |
| | 61 | 36.4 | 29.1 - 43.7 | 38.7 | 2.71 | 16 | 93.8 | | | |
| BINDING SITE, THE | 60 | 205 | 164 - 246 | 223 | 12.3 | 14 | 85.7 | 78.6 | | |
| | 61 | 36.4 | 29.1 - 43.7 | 38.9 | 6.27 | 14 | 85.7 | | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 205 | 164 - 246 | 206 | 3.78 | 88 | 97.7 | 94.3 | | |
| | 61 | 36.4 | 29.1 - 43.7 | 36.6 | 3.72 | 88 | 95.5 | | | |
| ROCHE DIAGNOSTICS, ABBOTT | 60 | 205 | 164 - 246 | 194 | 5.01 | 39 | 92.3 | 87.2 | | |
| | 61 | 36.4 | 29.1 - 43.7 | 34.0 | 6.50 | 39 | 89.7 | | | |

Rate of success: 91,1%





| IgA - CSF (mg/l, N = 128) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 35.5 | 25.9 - 45.1 | 31.7 | 3.88 | 16 | 100 | 87.5 | | |
| | 61 | 4.34 | 3.17 - 5.51 | 4.68 | 6.82 | 16 | 87.5 | | | |
| BINDING SITE, THE | 60 | 35.5 | 25.9 - 45.1 | 37.5 | 12.5 | 11 | 81.8 | 72.7 | | |
| | 61 | 4.34 | 3.17 - 5.51 | 5.02 | 6.87 | 11 | 72.7 | | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 35.5 | 25.9 - 45.1 | 23.2 | 17.5 | 73 | 24.7 | 23.3 | | |
| | 61 | 4.34 | 3.17 - 5.51 | 4.14 | 7.83 | 73 | 95.9 | | | |
| ROCHE DIAGNOSTICS | 60 | 35.5 | 25.9 - 45.1 | 37.5 | 4.27 | 28 | 92.9 | 89.3 | | |
| | 61 | 4.34 | 3.17 - 5.51 | 4.51 | 4.48 | 28 | 89.3 | | | |

Rate of success: 50%



| IgM - CSF (mg/l, N = 137) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 8.86 | 5.94 - 11.8 | 9.40 | 11.8 | 16 | 87.5 | 81.3 | | |
| | 61 | 2.03 | 1.36 - 2.70 | 2.26 | 8.81 | 16 | 87.5 | | | |
| BINDING SITE, THE | 60 | 8.86 | 5.94 - 11.8 | 8.37 | 12.1 | 12 | 83.3 | 75.0 | | |
| | 61 | 2.03 | 1.36 - 2.70 | 1.81 | 9.06 | 12 | 83.3 | | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 8.86 | 5.94 - 11.8 | 8.96 | 10.7 | 80 | 96.3 | 93.8 | | |
| | 61 | 2.03 | 1.36 - 2.70 | 2.09 | 10.1 | 80 | 95.0 | | | |
| ROCHE DIAGNOSTICS | 60 | 8.86 | 5.94 - 11.8 | 8.65 | 4.22 | 29 | 89.7 | 86.2 | | |
| | 61 | 2.03 | 1.36 - 2.70 | 1.84 | 3.86 | 29 | 89.7 | | | |



Rate of success: 89,1%



| Albumin quotient (E-3, N = 161) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|--------|-------------------------|------|------|----------|-------|--|
| Collective | Sample | Target value | Target range | | Participants collective | | | Rate (%) | | |
| | | | | | AVG | CV | Num. | Sam. | total | |
| BECKMAN COULTER | 60 | 37.1 | 26.0 | - 48.2 | 39.0 | 3.46 | 17 | 100 | 100 | |
| | 61 | 5.12 | 3.58 | - 6.66 | 5.17 | 5.53 | 17 | 100 | | |
| BINDING SITE, THE | 60 | 37.1 | 26.0 | - 48.2 | 39.1 | 5.22 | 13 | 92.3 | 92.3 | |
| | 61 | 5.12 | 3.58 | - 6.66 | 5.40 | 8.19 | 13 | 92.3 | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 37.1 | 26.0 | - 48.2 | 37.6 | 5.16 | 84 | 96.4 | 96.4 | |
| | 61 | 5.12 | 3.58 | - 6.66 | 5.24 | 4.77 | 84 | 97.6 | | |
| ROCHE DIAGNOSTICS | 60 | 37.1 | 26.0 | - 48.2 | 35.1 | 5.19 | 43 | 95.3 | 90.7 | |
| | 61 | 5.12 | 3.58 | - 6.66 | 4.76 | 6.30 | 43 | 90.7 | | |
| other providers (1) | 60 | 37.1 | 26.0 | - 48.2 | 28.1 | 65.1 | 4 | | | |
| | 61 | 5.12 | 3.58 | - 6.66 | 4.00 | 61.8 | 4 | | | |



(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.

Rate of success: 94,4%





| IgG Quotient (E-3, N = 149) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|--------|-------------------------|------|------|----------|-------|--|
| Collective | Sample | Target value | Target range | | Participants collective | | | Rate (%) | | |
| | | | | | AVG | CV | Num. | Sam. | total | |
| BECKMAN COULTER | 60 | 19.5 | 13.7 | - 25.4 | 20.3 | 5.32 | 16 | 100 | 93.8 | |
| | 61 | 3.24 | 2.27 | - 4.21 | 3.48 | 4.71 | 16 | 93.8 | | |
| BINDING SITE, THE | 60 | 19.5 | 13.7 | - 25.4 | 21.1 | 14.8 | 13 | 92.3 | 84.6 | |
| | 61 | 3.24 | 2.27 | - 4.21 | 3.44 | 10.9 | 13 | 84.6 | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 19.5 | 13.7 | - 25.4 | 19.5 | 4.76 | 85 | 95.3 | 95.3 | |
| | 61 | 3.24 | 2.27 | - 4.21 | 3.24 | 4.01 | 85 | 97.6 | | |
| ROCHE DIAGNOSTICS; ABBOTT | 60 | 19.5 | 13.7 | - 25.4 | 18.8 | 4.51 | 35 | 97.1 | 91.4 | |
| | 61 | 3.24 | 2.27 | - 4.21 | 3.10 | 5.52 | 35 | 91.4 | | |

Rate of success: 93,3%





| IgA Quotient (E-3, N = 124) | | | | | | | | | | |
|---------------------------------|--------|--------------|--------------|--------|-------------------------|------|------|----------|-------|--|
| Collective | Sample | Target value | Target range | | Participants collective | | | Rate (%) | | |
| | | | | | AVG | CV | Num. | Sam. | total | |
| BECKMAN COULTER | 60 | 24.2 | 16.9 | - 31.5 | 22.3 | 10.3 | 16 | 100 | 93.8 | |
| | 61 | 2.46 | 1.72 | - 3.20 | 2.50 | 13.9 | 16 | 93.8 | | |
| BINDING SITE, THE | 60 | 24.2 | 16.9 | - 31.5 | 28.0 | 14.5 | 10 | 90.0 | 80.0 | |
| | 61 | 2.46 | 1.72 | - 3.20 | 2.75 | 9.60 | 10 | 90.0 | | |
| ROCHE DIAGNOSTICS | 60 | 24.2 | 16.9 | - 31.5 | 26.0 | 5.35 | 26 | 96.2 | 88.5 | |
| | 61 | 2.46 | 1.72 | - 3.20 | 2.41 | 5.06 | 26 | 88.5 | | |
| SIEMENS (CSF assay) | 60 | 24.2 | 16.9 | - 31.5 | 22.2 | 25.0 | 28 | 82.1 | 82.1 | |
| | 61 | 2.46 | 1.72 | - 3.20 | 2.79 | 5.56 | 28 | 96.4 | | |
| SIEMENS (serum assay) | 60 | 24.2 | 16.9 | - 31.5 | 13.5 | 18.4 | 35 | 17.1 | 14.3 | |
| | 61 | 2.46 | 1.72 | - 3.20 | 1.79 | 9.50 | 35 | 62.9 | | |
| without information about assay | 60 | 20.5 | 14.4 | - 26.7 | 15.8 | 34.4 | 9 | 33.3 | 11.1 | |
| | 61 | 2.35 | 1.65 | - 3.06 | 2.21 | 35.8 | 9 | 55.6 | | |

Rate of success: 60,5%





| IgM Quotient (E-3, N = 132) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 12.2 | 8.54 - 15.9 | 13.0 | 10.9 | 16 | 93.8 | 87.5 | | |
| | 61 | 2.16 | 1.51 - 2.81 | 2.50 | 4.96 | 16 | 87.5 | | | |
| BINDING SITE, THE | 60 | 12.2 | 8.54 - 15.9 | 13.8 | 16.5 | 11 | 90.9 | 81.8 | | |
| | 61 | 2.16 | 1.51 - 2.81 | 2.22 | 15.0 | 11 | 90.9 | | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 12.2 | 8.54 - 15.9 | 11.4 | 12.1 | 78 | 93.6 | 91.0 | | |
| | 61 | 2.16 | 1.51 - 2.81 | 2.04 | 12.6 | 78 | 94.9 | | | |
| ROCHE DIAGNOSTICS | 60 | 12.2 | 8.54 - 15.9 | 13.6 | 4.69 | 27 | 96.3 | 92.6 | | |
| | 61 | 2.16 | 1.51 - 2.81 | 2.28 | 3.90 | 27 | 92.6 | | | |

Rate of success: 90,2%





| Albumin (g/l, N = 183) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 34.0 | 27.2 - 40.8 | 33.9 | 4.22 | 16 | 100 | 100 | | |
| | 61 | 44.4 | 35.5 - 53.3 | 44.6 | 3.25 | 16 | 100 | | | |
| BINDING SITE, THE | 60 | 34.0 | 27.2 - 40.8 | 32.6 | 5.40 | 12 | 100 | 100 | | |
| | 61 | 44.4 | 35.5 - 53.3 | 43.0 | 5.40 | 12 | 100 | | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 34.0 | 27.2 - 40.8 | 34.3 | 4.26 | 84 | 95.2 | 95.2 | | |
| | 61 | 44.4 | 35.5 - 53.3 | 44.7 | 4.25 | 84 | 96.4 | | | |
| ROCHE DIAGNOSTICS | 60 | 34.0 | 27.2 - 40.8 | 33.9 | 4.96 | 57 | 96.5 | 96.5 | | |
| | 61 | 44.4 | 35.5 - 53.3 | 44.3 | 4.29 | 57 | 96.5 | | | |
| other providers | 60 | 34.0 | 27.2 - 40.8 | 33.8 | 2.34 | 14 | 92.9 | 92.9 | | |
| | 61 | 44.4 | 35.5 - 53.3 | 44.0 | 2.41 | 14 | 100 | | | |

Rate of success: 96,2%




| IgG (g/l, N = 160) | | | | | | | | | | |
|--------------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 10.5 | 8.61 - 12.4 | 10.4 | 1.83 | 16 | 93.8 | 93.8 | | |
| | 61 | 11.2 | 9.18 - 13.2 | 11.2 | 2.44 | 16 | 93.8 | | | |
| BINDING SITE, THE | 60 | 10.5 | 8.61 - 12.4 | 10.7 | 4.04 | 13 | 84.6 | 84.6 | | |
| | 61 | 11.2 | 9.18 - 13.2 | 11.1 | 4.95 | 13 | 100 | | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 10.5 | 8.61 - 12.4 | 10.6 | 3.83 | 86 | 97.7 | 97.7 | | |
| | 61 | 11.2 | 9.18 - 13.2 | 11.3 | 3.58 | 86 | 97.7 | | | |
| ROCHE DIAGNOSTICS, ABBOTT | 60 | 10.5 | 8.61 - 12.4 | 10.4 | 4.40 | 45 | 97.8 | 97.8 | | |
| | 61 | 11.2 | 9.18 - 13.2 | 11.0 | 3.87 | 45 | 97.8 | | | |

Rate of success: 96,3%




| IgA (g/l, N = 132) | | | | | | | | | | |
|----------------------------------|--------|--------------|--------------|-------------------------|------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 1.44 | 1.15 - 1.73 | 1.44 | 11.0 | 16 | 93.8 | 87.5 | | |
| | 61 | 1.90 | 1.52 - 2.28 | 1.90 | 10.1 | 16 | 93.8 | | | |
| BINDING SITE, THE | 60 | 1.36 | 1.09 - 1.63 | 1.36 | 7.28 | 10 | 80.0 | 80.0 | | |
| | 61 | 1.80 | 1.44 - 2.16 | 1.80 | 5.33 | 10 | 100 | | | |
| ROCHE DIAGNOSTICS | 60 | 1.48 | 1.18 - 1.78 | 1.48 | 7.09 | 33 | 93.9 | 93.9 | | |
| | 61 | 1.93 | 1.54 - 2.32 | 1.93 | 6.84 | 33 | 93.9 | | | |
| SIEMENS, analysed with CSF assay | 60 | 1.11 | 0.888 - 1.33 | 1.11 | 11.2 | 27 | 88.9 | 88.9 | | |
| | 61 | 1.49 | 1.19 - 1.79 | 1.49 | 6.64 | 27 | 92.6 | | | |
| SIEMENS, analysed with Ser assay | 60 | 1.74 | 1.39 - 2.09 | 1.74 | 2.59 | 34 | 94.1 | 94.1 | | |
| | 61 | 2.30 | 1.84 - 2.76 | 2.30 | 3.35 | 34 | 97.1 | | | |
| other providers | 60 | 1.44 | 1.15 - 1.73 | 1.44 | 27.3 | 12 | 58.3 | 41.7 | | |
| | 61 | 1.93 | 1.54 - 2.32 | 1.93 | 32.8 | 12 | 50.0 | | | |

Rate of success: 86,4%



| IgM (g/l, N = 140) | | | | | | | | | | |
|--------------------------------------|--------|--------------|---------------|-------------------------|-------|------|----------|-------|--|--|
| Collective | Sample | Target value | Target range | Participants collective | | | Rate (%) | | | |
| | | | | AVG | CV | Num. | Sam. | total | | |
| BECKMAN COULTER | 60 | 0.740 | 0.548 - 0.932 | 0.735 | 5.44 | 16 | 93.8 | 87.5 | | |
| | 61 | 0.948 | 0.702 - 1.19 | 0.898 | 6.24 | 16 | 93.8 | | | |
| BINDING SITE, THE | 60 | 0.740 | 0.548 - 0.932 | 0.629 | 12.6 | 11 | 81.8 | 72.7 | | |
| | 61 | 0.948 | 0.702 - 1.19 | 0.812 | 14.7 | 11 | 81.8 | | | |
| SIEMENS CSF Assay | 60 | 0.740 | 0.548 - 0.932 | 0.764 | 16.6 | 8 | 87.5 | 87.5 | | |
| | 61 | 0.948 | 0.702 - 1.19 | 0.938 | 19.4 | 8 | 87.5 | | | |
| SIEMENS (Dade Behring, Bayer Health) | 60 | 0.740 | 0.548 - 0.932 | 0.795 | 4.65 | 68 | 97.1 | 95.6 | | |
| | 61 | 0.948 | 0.702 - 1.19 | 1.04 | 4.62 | 68 | 97.1 | | | |
| ROCHE DIAGNOSTICS | 60 | 0.740 | 0.548 - 0.932 | 0.649 | 6.93 | 34 | 97.1 | 94.1 | | |
| | 61 | 0.948 | 0.702 - 1.19 | 0.833 | 7.08 | 34 | 94.1 | | | |
| other providers (1) | 60 | 0.740 | 0.548 - 0.932 | 0.730 | 0.000 | 3 | | | | |
| | 61 | 0.948 | 0.702 - 1.19 | 0.930 | 2.47 | 3 | | | | |

Rate of success: 92,1%



(1) In individual cases is a statistically valid valuation with consensus value not given, because size of the collective < 8 values.



Cerebrospinal Fluid Analysis 01 - Protein Analysis

Interpretation of the report (N = 160, Rate of success: 88,8%)

Sample 60

| Collective | Blood/CSF-barrier dysfunction | inflammatory CNS process | normal CSF | implausible combination of the quotients | total |
|---------------|-------------------------------|--------------------------|------------|--|-------|
| all providers | 146 ● | 56 | 4 | 4 | 210 |

Sample 61

| Collective | inflammatory CNS process | normal CSF | implausible combination of the quotients | Blood/CSF-barrier dysfunction | total |
|---------------|--------------------------|------------|--|-------------------------------|-------|
| all providers | 110 ● | 35 ● | 9 ● | 4 | 158 |

The point corresponds to the correct result, the horizontal bar corresponds to your specification, the vertical bar corresponds to your collective

normal quotient of (N = 146, Rate of success: 63,7%)

Sample 60

| Collective | IgG | IgM | IgA | Albumin | total |
|---------------|-------|------|------|---------|-------|
| all providers | 106 ● | 92 ● | 48 ● | 7 | 253 |

Sample 61

| Collective | Albumin | IgG | IgA | IgM | total |
|---------------|---------|-----|-----|-----|-------|
| all providers | 135 ● | 122 | 62 | 15 | 334 |

The point corresponds to the correct result, the horizontal bar corresponds to your specification, the vertical bar corresponds to your collective

intrathecal synthesis of (N = 142, Rate of success: 76,8%)

Sample 60

| Collective | IgG | IgA | IgM | no evidence of intrathecal immunoglobulin synthesis | total |
|---------------|-----|------|-----|---|-------|
| all providers | 1 | 52 ● | 2 | 74 ● | 129 |

Sample 61

| Collective | IgM | IgA | no evidence of intrathecal immunoglobulin synthesis | IgG | total |
|---------------|-------|------|---|-----|-------|
| all providers | 111 ● | 58 ● | 18 ● | 15 | 202 |

The point corresponds to the correct result, the horizontal bar corresponds to your specification, the vertical bar corresponds to your collective